Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Diseases of the Esophagus

Camrelizumab, Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma (Esprit): A Phase Ii, Single-Arm Study

View Full Paper
Ask AI
Bookmark
Share

Authors

JMJianqun MaYYYingnan YangJZJinfeng Zhang

Discussion

Loading...

Member takes

Overview

Phase II study shows improved overall survival and disease-free survival in locally advanced ESCC, suggesting the efficacy of neoadjuvant therapy.

Key Points

  • The neoadjuvant therapy led to a pathological complete remission rate of 27.4% in patients with locally advanced esophageal cancer.
  • Among 62 surgical patients, the overall response rate was 48.4%, with a high disease control rate of 98.4%.
  • This single-arm phase II study involved a regimen of camrelizumab, paclitaxel, and nedaplatin administered for 2-4 cycles before surgery.
  • The results support further research into this combined therapy as it demonstrates significant survival benefits in patients.

Cite This Study

Ma et al. (2025) studied this question.

synapsesocial.com/papers/68c23cf6b210217d6478b7b2https://doi.org/10.1093/dote/doaf061.330
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1272. CAMRELIZUMAB, PACLITAXEL AND NEDAPLATIN AS CONVERSION THERAPY FOR LOCALLY ADVANCED/ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A PHASE II, SINGLE-ARM STUDY2025
  2. 2223. CAMRELIZUMAB AND CHEMOTHERAPY AS NEOADJUVANT TREATMENT FOR LOCALLYADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)A SINGLE-ARM, PHASE II TRIAL2025
  3. 3Analysis of camrelizumab in neoadjuvant chemotherapy for esophageal cancer: A retrospective cohort study2025 · 1 citations
  4. 4236. SAFETY AND EFFICACY OF CAMRELIZUMAB COMBINED WITH RADIOTHERAPY AS NEOADJUVANT THERAPY FOR LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA2025
  5. 5107. CAMRELIZUMAB AND LOW-DOSE RADIOTHERAPY WITH CONCURRENT CHEMORADIOTHERAPY FOR LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA (NICE-RT STUDY): PRELIMINARY RESULTS2025